Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
Sign in with Google. Opens in new tab
ENTITY
SMARTSCORE: 2.4/5
Mesoblast Ltd (MSB AU)
Watchlist
Contact IR
66
Analysis
Health Care
•
Australia
Mesoblast Limited provides biomedical services. The Company develops drugs for cardiovascular diseases, oncology, hematology, and spine orthopedic disorders treatment. Mesoblast conducts its business worldwide.
more
Watchlist
Contact IR
All
Insights
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
•
CIMIC Group Ltd
•
23 Feb 2022 15:33
CIMIC (CIM AU) Replacement in ASX200
CIMIC's takeover by Hochtief triggers another index change in ASX200 - likely sometime in April. This brings forward the first intra-quarter ASX200...
Travis Lundy
Follow
354 Views
Share
bullish
•
Nongfu Spring
•
19 Feb 2022 20:23
Index Rebalance & ETF Flow Recap: HSI, HSCEI, HSTECH, HSCI, S&P/ASX, SET50, LIC, SBI Sumishin, Crown
This recap highlights Insights covering Asian index rebalances (announcements/ forecasts/ IPO Fast Entry/ M&A driven changes). We also highlight...
Brian Freitas
Follow
589 Views
Share
bullish
•
HomeCo Daily Needs REIT
•
19 Feb 2022 14:40
The Weird Ways of the Aventus/HomeCo Daily Needs Index Rebalances (ASX200)
Aventus and Homeco Daily Needs now have the last doc/approval needed to proceed with their merger. The last day of trading for Aventus is 23 Feb....
Travis Lundy
Follow
411 Views
Share
bullish
•
Mesoblast Ltd
•
19 Feb 2022 08:54
Mesoblast (MSB AU): Preparing for Re-Submission of Biologics License Application for Ryoncil
Mesoblast is preparing for biologics license application for two of its pipeline candidates. The company believes it has generated substantial new...
Tina Banerjee
Follow
381 Views
Share
bullish
•
HomeCo Daily Needs REIT
•
18 Feb 2022 12:12
S&P/ASX Indices: Quiddity Leaderboard for March 2022 Rebalance (Final)
A final look at the leading candidates who could become Adds/Deletes during the March 2022 Rebalance and other potential irregular changes.
Janaghan Jeyakumar, CFA
Follow
629 Views
Share
First
Previous
4
5
6
7
8
9
10
Next
Last
For Institutional Investors and Financial Services
For Corporate IR and Strategy
For Private Wealth Intermediaries
Pricing
Who We Are
Careers
FAQs
Research Provider Solutions
Syndicate your Publications
Compliance
Terms of Use
Privacy Policy
Press Kit
RSS Feeds
Request a Free Trial
Avail a Transition Account
Guest Posts on Smartkarma
Other Enquiries
Join TL;DR Community
Free Weekly Newsletters
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.54.9
x